On January 24th, AI Pharmaceutical R&D company XtalPi announced that it has completed approximately $15 million in Series B financing in the near future. This round of financing was led by Sequoia Capital China Fund (hereinafter referred to as “Sequoia Chinaâ€). , Google and investment, A round of investment, Tencent continues to invest in this round. The company currently has a total financing of more than 20 million US dollars, becoming one of the companies with the highest total financing amount in AI pharmaceutical research and development. The existing investors of Jingtai Technology also include Zhenge Fund and Fengrui Capital.
Founded in 2014 on the MIT campus, Jingtai Technology is committed to creating a new generation of Intelligent Drug Discovery and Development (ID4) technology to address efficiency and success rates in preclinical drug research. The company combines quantum physics, artificial intelligence and ultra-large-scale cloud computing to achieve fast and accurate prediction of important properties of small molecule drugs. Jingtai Technology has established stable and in-depth cooperation with many of the world's top pharmaceutical companies and new drug research institutions.
After completing this round of financing, Jingtai Technology will continue to promote cooperative research and development projects with international pharmaceutical companies and research institutions, and expand to the upstream and downstream links of drug research and development. On the one hand, Jingtai Technology will build a crystallization laboratory guided by high-precision prediction, giving drug developers unprecedented drug solid-phase design capabilities, thereby further improving R&D efficiency and project success rate; Accuracy calculation data develops new algorithm applications and provides a richer solution for new drug development.
Wen Shuhao, co-founder and chairman of Jingtai Technology, said: "It is a great affirmation of our technology to be able to obtain the support of top investors in artificial intelligence and computer science such as Sequoia China, Google, and Tencent. We are also looking forward to the future. They further cooperate."
Shen Nanpeng, global managing partner of Sequoia Capital, said: “The investment of Sequoia China in Jingtai Technology reflects our optimistic development prospects of artificial intelligence to drive the transformation of the pharmaceutical industry. The company has advantages in technology, team and business model. A leader in this field. I look forward to Sequoia China to help Jingtai Technology achieve value and grow into a successful and influential company."
Lin Yifan of Google Enterprise Investment Development said: "Jingtai Technology's artificial intelligence platform is a powerful drug development tool, and many important researchers have begun to apply. Their drug development technologies, such as ID4, can promote new drug development capabilities and Efficiency while reducing costs. We are honored to work with this powerful team and look forward to their future development."
“After obtaining Ten-A's investment in Tencent, Jingtai Technology has developed rapidly, and innovation in artificial intelligence drug research and development technology has been recognized by world-renowned pharmaceutical companies,†said Li Zhaohui, managing partner of Tencent Investment. "Tencent's additional investment in this round is that we are optimistic about the innovation ability and execution ability of Jingtai Technology team, and also have confidence in the future development of artificial intelligence-driven drug research and development." (CBN)
Zhejiang ocean family co.,ltd , https://www.ocean-family.com